- Launched Neurosterix with Perceptive Advisors to accelerate the development of M4PAM for schizophrenia
- Indivior selected GABA B PAM drug candidate for development in substance use disorders
- Addex selected independent GABAB PAM drug candidate for development in chronic cough
Register to read this story and more for free.
Signing up for an account helps us improve your browsing experience.
ContinueOR
See our subscription options.
Already have an account? Log in here